NEW DELHI – In a move that could cost India's generics industry more than $1 billion, the European Commission (EC) has banned 700 Indian generic drugs, based on flaws detected during inspections of clinical trials conducted by Hyderabad-based contract research organization GVK Biosciences Ltd. The flaws pertained mainly to "data manipulations" of electrocardiograms conducted of patients during studies on several generic medicines. (See BioWorld Today, Feb. 4, 2015.)